PROLOR Biotech to Host Investor Conference Call

NES-ZIONA, Israel, Aug. 24, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will host an investor conference call and webcast on September 7, 2011 to review recently announced corporate developments, including the positive results from the company's Phase II trial of hGH-CTP, its long-acting version of human growth hormone.

A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and webcast will begin at 8:30 am EDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit the Investors section of PROLOR's website at

Those investors who prefer to participate by telephone, or who want to ask questions during the conference call, should dial the following number approximately 10 minutes prior to the scheduled start time and request to join the PROLOR Biotech call at: 1-800-860-2442 (within the US) or 1-412-858-4600 (for international calls).

A copy of the company's updated corporate presentation, which includes a top-line analysis of data from the Phase II trial of hGH-CTP, will be available at the start of the call on September 7, 2011 under "Presentations" in the Investors section of PROLOR's website at  


PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is completing Phase II clinical development, as well as Factor VII, Factor IX, interferon beta, erythropoietin, an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development. For more information, visit



Shai Novik, President      

Barbara Lindheim

PROLOR Biotech, Inc.              

GendeLLindheim BioCom Partners

Tel: +1 866 644-7811  

+1 212 918-4650

Email: [email protected]                                      

[email protected]


Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.